
Day One’s Year in Review: Unveiling Q4 & Full-Year 2024 Financial Results and Corporate Advancements
OJEMDA™ (torvorafenib): A New Milestone in Cancer Treatment In the ever-evolving landscape of cancer research and treatment, a significant achievement was made during Q4 2024 and the full year 2024. The net product revenues for OJEMDA™ (torvorafenib) reached an impressive $29.0 million and $57.2 million, respectively. What is OJEMDA™ (torvorafenib)? OJEMDA™, a trademarked name for…